Epigenetically defined genomic loci in CAR-T cells

Epigenetically defined genomic loci in CAR-T cells refer to specific regions of the genome, such as enhancers and promoters, whose chemical modifications (e.g., DNA methylation and histone acetylation) dictate the functional state and therapeutic potential of engineered T-cells (Zebley et al., 2021, Nature). These loci act as critical regulatory nodes that govern the transition of CAR-T cells from an effector state to either a long-lived memory state or a dysfunctional, exhausted state (Lynn et al., 2019, Nature). By mapping these loci using techniques like ATAC-seq or ChIP-seq, researchers can identify epigenetic signatures that predict patient response to therapy and long-term persistence (Prinzing et al., 2021, Cancer Cell). While not a single protein target, these loci are increasingly viewed as targets for precision engineering, where CRISPR-based epigenetic editors are used to rewrite the epigenetic code at specific sites to prevent T-cell exhaustion (Belk et al., 2022, Cell). This approach aims to overcome the immunosuppressive tumor microenvironment by stabilizing favorable gene expression programs (Mackall & Miklos, 2017, JCI). Consequently, these genomic regions are central to the development of next-generation, epigenetically-armored CAR-T cell therapies.

Other names

CAR-T cell epigenetic landscapeCAR-T chromatin accessibility regionsEpigenetic signatures of T-cell exhaustionDifferentially methylated regions in CAR-T cellsCAR-T regulatory genomic elements

Modulation of chromatin accessibility and DNA methylation at specific regulatory elements to reprogram T-cell differentiation and prevent terminal exhaustion.